Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANXENE vs XANAX XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability.
Anxiety disorders,Short-term relief of anxiety symptoms,Alcohol withdrawal syndrome,Adjunctive treatment for partial seizures
Panic disorder with or without agoraphobia
7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.
0.5-1 mg orally once daily; may increase at 3-4 day intervals; maximum 10 mg/day
Terminal elimination half-life of the active metabolite desmethyldiazepam is 30-200 hours (mean ~100 hours); parent drug clorazepate is rapidly hydrolyzed and has negligible half-life. Accumulation occurs with repeated dosing, leading to delayed peak effects and prolonged sedation.
Mean terminal elimination half-life is 11.2 hours (range 6.3-15.8 hours). The extended-release formulation provides sustained therapeutic concentrations with once-daily dosing.
Hepatic via oxidative metabolism; primarily by CYP3A4 and CYP2C19 to active metabolite nordazepam, then to oxazepam and others. Also undergoes glucuronidation.
Hepatic via CYP3A4; active metabolite alprazolam does not accumulate significantly.
Primarily renal (80-90% as conjugated metabolites, including oxazepam and desmethyldiazepam); biliary/fecal excretion accounts for <10%.
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of the dose. Fecal excretion is minimal (<10%).
Clorazepate and desmethyldiazepam: 95-98% bound to albumin.
80% bound to serum albumin.
Clorazepate: 0.2-0.3 L/kg. Desmethyldiazepam: 0.5-1.5 L/kg (large Vd indicates extensive tissue distribution).
Approximately 1.1 L/kg (range 0.9-1.3 L/kg), indicating extensive tissue distribution.
Oral: nearly 100% (prodrug completely hydrolyzed in gastric acid to desmethyldiazepam). Intramuscular: erratic and incomplete (approximately 50-70% bioavailability due to variable absorption).
Oral: Approximately 90% (absolute bioavailability).
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50% and use with caution.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: initiate at 0.5 mg once daily, titrate cautiously; GFR <15 m L/min: avoid use
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Child-Pugh Class A: initiate 0.5 mg once daily; Child-Pugh Class B: initiate 0.25 mg once daily; Child-Pugh Class C: avoid use
Children 9-12 years: 7.5 mg orally twice daily; increase to 7.5 mg three times daily if needed. Not recommended under 9 years.
Not FDA approved for patients <18 years; off-label doses: 0.125-0.5 mg/kg/day divided once daily; titrate slowly
Initiate at 3.75 mg orally 1 to 2 times daily; titrate slowly to avoid sedation and falls.
Initiate 0.25 mg once daily; titrate by 0.125 mg increments every 3-4 days; maximum 2 mg/day
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate alternative treatment options.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death; reserve for patients with inadequate alternative treatment options.
Risk of dependence and withdrawal seizures with abrupt discontinuation,CNS depressant effects may impair driving or operating machinery,Use caution in hepatic impairment,Avoid in pregnancy (risk of neonatal withdrawal and floppy infant syndrome),Potential for anterograde amnesia,Elderly patients at increased risk for adverse effects
Risks of dependence and withdrawal reactions,Risk of abuse and misuse,Concomitant use with CNS depressants,Risk of severe anaphylactic reactions,Use in patients with depression or suicidal ideation
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Severe hepatic impairment,Pregnancy (especially first trimester),Breastfeeding,Concomitant use with opioids unless alternative treatments are inadequate
Hypersensitivity to alprazolam or other benzodiazepines,Concurrent use with ketoconazole or itraconazole,Acute narrow-angle glaucoma
No specific food interactions. Grapefruit juice does not significantly affect metabolism. Fatty meals may delay absorption of oral clorazepate, but overall bioavailability not affected.
Grapefruit and grapefruit juice may increase alprazolam levels; avoid concurrent consumption. Alcohol intake should be strictly avoided due to additive CNS depressant effects. Take with or without food; however, high-fat meals may delay absorption but not the extent.
FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to physical dependence and withdrawal symptoms in the neonate, including floppy infant syndrome, respiratory depression, and feeding difficulties. Late pregnancy or near delivery: Risk of neonatal sedation, hypotonia, and withdrawal.
First trimester: Increased risk of oral cleft (absolute risk 0.5-1% vs 0.1-0.2% background). Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, respiratory depression, and neonatal sedation. Late third trimester or delivery: Risk of neonatal withdrawal and hypotonia.
Excreted in human milk. M/P ratio not established. Case reports indicate low milk levels (approx 4-10% of maternal weight-adjusted dose) but infant accumulation possible due to long half-life. Benefits of breastfeeding should be weighed against potential risks of sedation and poor feeding in the infant. Monitor infant for drowsiness, poor suckling, and weight loss.
Alprazolam is excreted in breast milk. M/P ratio approximately 0.36. Monitor infant for sedation, poor feeding, and weight gain. Use lowest effective dose and consider alternative agents if prolonged use required.
Due to increased volume of distribution and enhanced clearance, higher doses may be required during pregnancy to maintain efficacy, especially in the second and third trimesters. However, dose adjustment should be individualized and cautious because of potential fetal risks. Use the lowest effective dose for the shortest duration. Avoid high doses near term.
Increased clearance and decreased half-life in pregnancy may require dose increase. Titrate to clinical effect. Avoid use in labor due to neonatal depression risk.
TRANXENE (clorazepate) is a benzodiazepine prodrug that is decarboxylated in the stomach to the active metabolite N-desmethyldiazepam. Onset of action is relatively slow (1-2 hours) compared to diazepam. Due to its long half-life (up to 100 hours for active metabolite), accumulation is possible in elderly or hepatically impaired patients. Avoid in narrow-angle glaucoma. Abrupt discontinuation may precipitate withdrawal seizures.
XANAX XR (alprazolam extended-release) is indicated for panic disorder with or without agoraphobia. Due to its extended-release formulation, it has a slower onset and longer duration compared to immediate-release alprazolam. Dose conversion from immediate-release is not 1:1; total daily dose of immediate-release should be given once daily of XR. Avoid abrupt discontinuation to prevent withdrawal symptoms, including seizures. Monitor for CNS depression when co-administered with other CNS depressants. Use cautiously in patients with hepatic impairment or elderly due to reduced clearance.
Do not stop taking suddenly; taper under medical supervision to avoid withdrawal symptoms.,Avoid alcohol and other CNS depressants (e.g., opioids, sleep aids) as they increase sedation and respiratory depression risk.,May cause drowsiness, dizziness; avoid driving or operating machinery until effect is known.,Take with or without food. Do not crush or chew extended-release capsules.,Inform doctor if you have a history of substance abuse, liver disease, or glaucoma.,Use caution in elderly patients due to increased risk of falls and cognitive impairment.,Notify doctor immediately if you experience suicidal thoughts, unusual mood changes, or allergic reactions.
Take this medication exactly as prescribed, usually once daily in the morning.,Do not crush, chew, or break the extended-release tablets; swallow them whole.,Avoid alcohol and other CNS depressants while taking XANAX XR, as they can increase drowsiness and risk of overdose.,Do not stop taking this medication abruptly without consulting your doctor; withdrawal symptoms can occur.,This medication can be habit-forming; use only as directed and do not share with others.,Inform your doctor if you become pregnant or plan to become pregnant, as use during pregnancy may harm the fetus.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANXENE vs XANAX XR, answered by our medical review team.
TRANXENE is a Benzodiazepine Anxiolytic that works by Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.. XANAX XR is a Benzodiazepine Anxiolytic that works by Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANXENE and XANAX XR depend on the specific clinical indication. These are both Benzodiazepine Anxiolytic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANXENE is: 7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.. The standard adult dose of XANAX XR is: 0.5-1 mg orally once daily; may increase at 3-4 day intervals; maximum 10 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANXENE and XANAX XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANXENE is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimest. XANAX XR is classified as Category C. First trimester: Increased risk of oral cleft (absolute risk 0.5-1% vs 0.1-0.2% background). Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, respi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.